These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34555976)

  • 1. [Clinical evaluation of progestogens used in Menopausal Hormone Therapy (MHT)].
    Mueck AO
    Ther Umsch; 2021; 78(8):447-455. PubMed ID: 34555976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.
    Davey DA
    Womens Health (Lond); 2012 Mar; 8(2):169-89. PubMed ID: 22375720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy.
    Gompel A
    Climacteric; 2018 Aug; 21(4):321-325. PubMed ID: 29583028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is breast cancer risk the same for all progestogens?
    Stute P
    Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between menopausal hormone therapy and breast cancer: A nationwide population-based cohort study.
    Yuk JS
    Int J Gynaecol Obstet; 2024 Aug; 166(2):735-744. PubMed ID: 38469634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The choice of progestogen for HRT in menopausal women: breast cancer risk is a major issue.
    Ruan X; Mueck AO
    Horm Mol Biol Clin Investig; 2018 Aug; 37(1):. PubMed ID: 30120909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea-based cohort study.
    Yuk JS; Kim T; Cho H; Gwak G
    Eur J Endocrinol; 2024 Jan; 190(1):1-11. PubMed ID: 38128117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Candidate Genes in Breast Cancer Induced by Estrogen Plus Progestogens Using Bioinformatic Analysis.
    Deng Y; Huang H; Shi J; Jin H
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.
    L'Hermite M
    Climacteric; 2017 Aug; 20(4):331-338. PubMed ID: 28301216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menopausal hormone therapy and the risk of type 2 diabetes mellitus: Health Insurance Database in South Korea-based retrospective cohort study.
    Yuk JS; Kim JM
    Menopause; 2023 May; 30(5):497-505. PubMed ID: 36917757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progestogens for endometrial protection in combined menopausal hormone therapy: A systematic review.
    Stute P; Walker LJ; Eicher A; Pavicic E; Kolokythas A; Theis S; von Gernler M; von Wolff M; Vollrath S
    Best Pract Res Clin Endocrinol Metab; 2024 Jan; 38(1):101815. PubMed ID: 37634998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer risk during hormone therapy: experimental versus clinical data.
    Ruan X; Seeger H; Mueck AO
    Minerva Endocrinol; 2012 Mar; 37(1):59-74. PubMed ID: 22382615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
    Cordina-Duverger E; Truong T; Anger A; Sanchez M; Arveux P; Kerbrat P; Guénel P
    PLoS One; 2013; 8(11):e78016. PubMed ID: 24223752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The menopause: benefits and risks of estrogen-progestogen replacement therapy.
    Gambrell RD
    Fertil Steril; 1982 Apr; 37(4):457-74. PubMed ID: 7040116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Menopausal hormone therapy and cancer risk: An overestimated risk?
    Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
    Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progestogens in postmenopausal hormone therapy and the risk of breast cancer.
    Lambrinoudaki I
    Maturitas; 2014 Apr; 77(4):311-7. PubMed ID: 24485796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea-based cohort study.
    Yuk JS
    Int J Gynaecol Obstet; 2023 Aug; 162(2):502-513. PubMed ID: 36964935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
    Fournier A; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F
    J Clin Oncol; 2009 Nov; 27(31):5138-43. PubMed ID: 19752341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of estrogens and progestogens.
    L'Hermite M
    Maturitas; 1990 Sep; 12(3):215-46. PubMed ID: 2170823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.
    DeBono NL; Robinson WR; Lund JL; Tse CK; Moorman PG; Olshan AF; Troester MA
    J Womens Health (Larchmt); 2018 Mar; 27(3):377-386. PubMed ID: 28570827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.